Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
NYU Langone Health
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07504796CT.gov ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | — | Recruiting | — | — | — |
NCT06163820CT.gov Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases | — | Recruiting | — | — | — |
NCT06784648CT.gov Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT05896839CT.gov Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | — | Recruiting | — | — | — |
NCT07436390CT.gov IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma | — | Completed | — | — | — |
NCT05779423CT.gov Cryoablation+Ipilimumab+Nivolumab in Melanoma | — | Recruiting | — | — | — |
NCT05704933CT.gov Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | — | Completed | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05169957CT.gov Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | — | Completed | — | — | — |
NCT07422779CT.gov Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | — | Recruiting | — | — | — |
Show 67 more trialsShow fewer
NCT04697576CT.gov Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | — | Recruiting | — | — | — |
NCT04940299CT.gov Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04967196CT.gov Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | — | Terminated | — | — | — |
NCT04899921CT.gov Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | — | Terminated | — | — | — |
NCT04060407CT.gov CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) | — | Withdrawn | — | — | — |
NCT04511013CT.gov A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | — | Recruiting | — | — | — |
NCT05611229CT.gov Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | — | Completed | — | — | — |
NCT03993379CT.gov PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | — | Terminated | — | — | — |
NCT03816332CT.gov Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | — | Active Not Recruiting | — | — | — |
NCT03903640CT.gov Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | — | Terminated | — | — | — |
NCT03850691CT.gov Radiation and Combination Immunotherapy for Melanoma | — | Completed | — | — | — |
NCT03645928CT.gov Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03873818CT.gov Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | — | Completed | — | — | — |
NCT03724968CT.gov Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | — | Terminated | — | — | — |
NCT03646617CT.gov Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | — | Recruiting | — | — | — |
NCT03235245CT.gov Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | — | Active Not Recruiting | — | — | — |
NCT03597282CT.gov A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | — | Terminated | — | — | — |
NCT03425461CT.gov Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | — | Terminated | — | — | — |
NCT03445533CT.gov A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | — | Terminated | — | — | — |
NCT03326258CT.gov Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | — | Withdrawn | — | — | — |
NCT03728465CT.gov Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | — | Terminated | — | — | — |
NCT03126461CT.gov SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | — | Withdrawn | — | — | — |
NCT03526185CT.gov A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | — | Terminated | — | — | — |
NCT03297463CT.gov Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma | — | Withdrawn | — | — | — |
NCT03122522CT.gov A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | — | Active Not Recruiting | — | — | — |
NCT02631447CT.gov Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | — | Completed | — | — | — |
NCT02644967CT.gov A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02506153CT.gov Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02608437CT.gov A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients | — | Unknown | — | — | — |
NCT02224781CT.gov Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | — | Active Not Recruiting | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02304458CT.gov Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | — | Completed | — | — | — |
NCT02027935CT.gov CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02203604CT.gov High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | — | Terminated | — | — | — |
NCT02259231CT.gov RTA 408 Capsules in Patients With Melanoma - REVEAL | — | Completed | — | — | — |
NCT02278887CT.gov Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02107755CT.gov Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02073123CT.gov Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02054520CT.gov Immunotherapy Study for Patients With Stage IV Melanoma | — | Terminated | — | — | — |
NCT02117362CT.gov Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02097732CT.gov Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | — | Terminated | — | — | — |
NCT01838200CT.gov Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | — | Terminated | — | — | — |
NCT02094391CT.gov Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma | — | Completed | — | — | — |
NCT01689870CT.gov Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | — | Withdrawn | — | — | — |
NCT01810016CT.gov NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | — | Terminated | — | — | — |
NCT02158520CT.gov Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01950195CT.gov SRS (Stereotactic Radiosurgery) Plus Ipilimumab | — | Terminated | — | — | — |
NCT01940809CT.gov Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | — | Terminated | — | — | — |
NCT01927419CT.gov Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma | — | Completed | — | — | — |
NCT01844505CT.gov Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | — | Completed | — | — | — |
NCT01856023CT.gov HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT01783938CT.gov Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | — | Completed | — | — | — |
NCT01738139CT.gov Ipilimumab and Imatinib Mesylate in Advanced Cancer | — | Completed | — | — | — |
NCT01689974CT.gov Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | — | Terminated | — | — | — |
NCT01703507CT.gov Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma | — | Completed | — | — | — |
NCT01701674CT.gov Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | — | Completed | — | — | — |
NCT01621490CT.gov PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma | — | Completed | — | — | — |
NCT02009397CT.gov A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | — | Completed | — | — | — |
NCT02009384CT.gov Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox | — | Terminated | — | — | — |
NCT01497808CT.gov RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | — | Completed | — | — | — |
NCT01134614CT.gov Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT01743157CT.gov Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma | — | Completed | — | — | — |
NCT01216696CT.gov Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 | — | Completed | — | — | — |
NCT01654692CT.gov A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma | — | Completed | — | — | — |
NCT01119508CT.gov Ipilimumab + Temozolomide in Metastatic Melanoma | — | Completed | — | — | — |
NCT00871481CT.gov Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00039091CT.gov Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | NYU Langone Health | Approved | BB · 68 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Therapeutic Autologous Lymphocytes | Fred Hutchinson Cancer Center | P2 | BB |
| Montanide Isa 51 | Ludwig Institute for Cancer Research | P2 | BB |
| gp100 antigen | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →